Advertisement

Organisation › Details
Cambridge Enterprise Ltd.
Cambridge Enterprise is responsible for supporting the translation of University of Cambridge research to create social and economic impact with global significance. We do this by helping innovators, experts and entrepreneurs use commercial avenues to develop their ideas and expertise for the benefit of society, the economy, themselves and the University. Liaising with organisations both locally and globally, we offer expert advice and support in commercialisation and social enterprise, including help with academic consultancy services, the protection, development and licensing of ideas, venture building and venture funding. Deeply embedded in the UK’s leading innovation and entrepreneurial ecosystem and part of the University of Cambridge, we have strong relationships with the University, industry, investors, innovators and visionaries. *
![]() |
Start | 2006-10-01 established |
Group | University of Cambridge | |
![]() |
Industry | IP services |
Industry 2 | venture capital | |
![]() |
Person | Thomas, Iain (Univ Cambridge 201601 Head of Life Sciences at Cambridge Enterprise) |
Person 2 | Hardiman, Bradley (Univ Cambridge 201509 Investment Manager at Cambridge Enterprise Seed Funds) | |
![]() |
Region | Cambridge, Cambridgeshire |
Country | United Kingdom (GB) | |
Street | 3 Charles Babbage Road The Hauser Forum | |
City | CB3 0GT Cambridge | |
Tel | +44-1223-760339 | |
Address record changed: 2024-08-23 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: T-Therapeutics Ltd.. (11/15/23). "Press Release: T-Therapeutics Raises £48 Million Series A for Development of Next Generation TCR Therapeutics to Transform Cancer Treatment". Cambridge. | ||
Record changed: 2024-12-05 |
Advertisement

More documents for University of Cambridge
- [1] Zetta Genomics Ltd.. (2/8/24). "Press Release: Zetta Genomics Expands Second Seed Funding Round with Additional £1.8 Million"....
- [2] Spirea Ltd.. (6/14/22). "Press Release: Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer". Cambridge....
- [3] HexagonFab Ltd.. (4/20/21). "Press Release: HexagonFab Secures £1.9m (USD 2.6m) Seed Funding to Launch the Bolt". Cambridge & Zurich....
- [4] Cambridge Innovation Capital plc. (4/1/19). "Press Release: Cambridge Innovation Capital Completes £150 Million New Capital Raise"....
- [5] MorphoSys AG. (2/19/19). "Press Release: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire". Planegg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top